These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30479671)

  • 21. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    Howie LJ; Singh H; Bloomquist E; Wedam S; Amiri-Kordestani L; Tang S; Sridhara R; Sanchez J; Prowell TM; Kluetz PG; King-Kallimanis BL; Gao JJ; Ibrahim A; Goldberg KB; Theoret M; Pazdur R; Beaver JA
    J Clin Oncol; 2019 Dec; 37(36):3475-3483. PubMed ID: 31560580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.
    Gao HF; Lin YY; Zhu T; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
    Breast; 2021 Oct; 59():165-175. PubMed ID: 34271289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
    Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
    ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development of CDK4/6 inhibitor for breast cancer.
    Iwata H
    Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.
    Hu Q; Kang W; Wang Q; Luo T
    BMJ Open; 2022 May; 12(5):e056374. PubMed ID: 35636793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
    Hill A; Gutierrez E; Liu J; Sammons S; Kimmick G; Sedrak MS
    Drugs Aging; 2020 May; 37(5):349-358. PubMed ID: 32227289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early breast cancer in the elderly: assessment and management considerations.
    Albrand G; Terret C
    Drugs Aging; 2008; 25(1):35-45. PubMed ID: 18184027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    Nagaraj G; Ma CX
    Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an
    Awada A; Gligorov J; Jerusalem G; Preusser M; Singer C; Zielinski C
    ESMO Open; 2019; 4(6):e000565. PubMed ID: 31798979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
    Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N
    Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():3-11. PubMed ID: 30288930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.